Codexis, Inc. (NASDAQ:CDXS) Director Sells $234,162.04 in Stock

Codexis, Inc. (NASDAQ:CDXS) Director Byron L. Dorgan sold 16,702 shares of Codexis stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $14.02, for a total value of $234,162.04. Following the completion of the sale, the director now directly owns 153,838 shares in the company, valued at approximately $2,156,808.76. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

NASDAQ CDXS opened at $13.27 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 7.37 and a quick ratio of 7.34. The business’s 50 day moving average price is $15.95 and its 200-day moving average price is $14.94. Codexis, Inc. has a fifty-two week low of $12.46 and a fifty-two week high of $22.38.

A number of research firms have issued reports on CDXS. HC Wainwright reaffirmed a “buy” rating and issued a $22.50 price objective on shares of Codexis in a research note on Tuesday, December 24th. Zacks Investment Research downgraded Codexis from a “buy” rating to a “hold” rating in a research note on Thursday, January 30th. BidaskClub downgraded Codexis from a “sell” rating to a “strong sell” rating in a research report on Thursday, February 13th. Finally, ValuEngine raised Codexis from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 31st.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Aigen Investment Management LP bought a new position in shares of Codexis during the 4th quarter valued at approximately $27,000. Great West Life Assurance Co. Can increased its position in shares of Codexis by 86.9% during the 4th quarter. Great West Life Assurance Co. Can now owns 3,446 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 1,602 shares during the last quarter. Marshall Wace North America L.P. bought a new position in shares of Codexis during the 4th quarter valued at approximately $57,000. Exchange Traded Concepts LLC bought a new position in shares of Codexis during the 4th quarter valued at approximately $65,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Codexis by 135.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,057 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 2,913 shares during the last quarter. 87.45% of the stock is currently owned by hedge funds and other institutional investors.

About Codexis

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Featured Story: S&P/ASX 200 Index

Insider Buying and Selling by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.